Article

ASCO: Novel Drug Safe, Promising in ALL

An investigational immunotherapy was well tolerated and active in patients with acute lymphoblastic leukemia (ALL), a researcher said here.

In a small phase II study, the bi-specific antibody blinatumomab had an "exceptionally high response rate," said Max Topp, MD, of University Hospitals of Wuerzburg in Wuerzburg, Germany.

Over all doses, 72% of the study's 36 patients had a complete response or a hematological complete response within two cycles of treatment, Topp reported at the annual meeting of the American Society of Clinical Oncology. The proportion was slightly higher — 74% -- among the 23 patients who had the safest dose from the start.

Read the full story: http://hcp.lv/JLNsld

Source: MedPage Today

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Mehmet Oz, MD, MBA
Hira Ghani, DO, discusses underdiagnosed skin conditions in children
Nicole Bajic, MD
World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com
2 experts in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo